Ubs Group Ag Intercept Pharmaceuticals, Inc. Call Options Transaction History

Ubs Group Ag

2 transactions

Quarter	Operation	Price Per call	calls change	calls Held	SEC Form
Q3 2021 Nov 15, 2021	SELL	$12.99 - $20.47 $5.66 Million - $8.93 Million	-436,040 Reduced 75.29%	143,080 $2.13 Million
Q1 2017 Nov 14, 2017	BUY	N/A	579,120	579,120 $65.5 Million

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.